Seer Redefining Deep Unbiased Proteomics with Launch of New Proteograph Workflow at ASMS 2025, Enabling Previously Unattainable Scale and Efficiency
Seer (NASDAQ: SEER) has unveiled its new Proteograph® Product Suite, featuring the Proteograph ONE Assay and SP200 Automation Instrument at ASMS 2025. The enhanced platform achieves groundbreaking improvements in proteomic analysis capabilities, processing over 1,000 samples per week per instrument - double the previous throughput. The new workflow reduces per-sample analysis costs by 60% compared to its 2021 release while identifying up to 10 times more proteins than traditional mass spec workflows.
Key advancements include automated run times under 5 hours for 80-sample batches, reduced operator-induced variability, and enhanced reproducibility. The system enables large-scale biomarker discovery, longitudinal disease studies, and comprehensive multi-center research. The new Proteograph Product Suite will be commercially available from June 1, 2025, through direct purchases and Seer's Technology Access Center.
Seer (NASDAQ: SEER) ha presentato la sua nuova Proteograph® Product Suite, che include il Proteograph ONE Assay e lo strumento di automazione SP200, durante ASMS 2025. La piattaforma migliorata offre progressi rivoluzionari nelle capacità di analisi proteomica, processando oltre 1.000 campioni a settimana per strumento, raddoppiando la produttività rispetto al passato. Il nuovo flusso di lavoro riduce i costi di analisi per campione del 60% rispetto alla versione del 2021, identificando fino a 10 volte più proteine rispetto ai metodi tradizionali di spettrometria di massa.
Tra i principali miglioramenti si annoverano tempi di esecuzione automatizzati inferiori a 5 ore per batch da 80 campioni, una riduzione della variabilità indotta dall’operatore e una maggiore riproducibilità. Il sistema supporta la scoperta su larga scala di biomarcatori, studi longitudinali sulle malattie e ricerche multi-centro complete. La nuova Proteograph Product Suite sarà disponibile commercialmente dal 1° giugno 2025, tramite acquisti diretti e il Technology Access Center di Seer.
Seer (NASDAQ: SEER) ha presentado su nueva Proteograph® Product Suite, que incluye el Proteograph ONE Assay y el instrumento de automatización SP200, en ASMS 2025. La plataforma mejorada ofrece avances revolucionarios en capacidades de análisis proteómico, procesando más de 1,000 muestras por semana por instrumento, duplicando el rendimiento anterior. El nuevo flujo de trabajo reduce los costos de análisis por muestra en un 60% en comparación con la versión de 2021, identificando hasta 10 veces más proteínas que los métodos tradicionales de espectrometría de masas.
Las principales mejoras incluyen tiempos de ejecución automatizados de menos de 5 horas para lotes de 80 muestras, reducción de la variabilidad inducida por el operador y mayor reproducibilidad. El sistema permite el descubrimiento a gran escala de biomarcadores, estudios longitudinales de enfermedades e investigaciones multicéntricas completas. La nueva Proteograph Product Suite estará disponible comercialmente a partir del 1 de junio de 2025, mediante compras directas y el Technology Access Center de Seer.
Seer (NASDAQ: SEER)는 ASMS 2025에서 Proteograph ONE Assay 및 SP200 자동화 기기를 포함한 새로운 Proteograph® 제품군을 공개했습니다. 향상된 플랫폼은 단일 기기당 주당 1,000개 이상의 샘플을 처리하여 이전 처리량의 두 배에 달하는 획기적인 프로테오믹 분석 능력을 제공합니다. 2021년 출시 버전과 비교해 샘플당 분석 비용을 60% 절감하면서 기존 질량 분석 워크플로우보다 최대 10배 더 많은 단백질을 식별합니다.
주요 개선 사항으로는 80개 샘플 배치에 대해 5시간 미만의 자동 실행 시간, 작업자에 의한 변동성 감소, 향상된 재현성이 포함됩니다. 이 시스템은 대규모 바이오마커 발견, 장기 질병 연구 및 종합적인 다기관 연구를 지원합니다. 새로운 Proteograph 제품군은 2025년 6월 1일부터 직접 구매와 Seer의 Technology Access Center를 통해 상업적으로 이용 가능합니다.
Seer (NASDAQ : SEER) a dévoilé sa nouvelle suite de produits Proteograph®, comprenant le Proteograph ONE Assay et l’instrument d’automatisation SP200, lors de l’ASMS 2025. Cette plateforme améliorée offre des avancées révolutionnaires dans les capacités d’analyse protéomique, traitant plus de 1 000 échantillons par semaine et par instrument, soit le double du débit précédent. Le nouveau flux de travail réduit les coûts d’analyse par échantillon de 60% par rapport à la version de 2021, tout en identifiant jusqu’à 10 fois plus de protéines que les méthodes traditionnelles de spectrométrie de masse.
Les principales améliorations incluent des temps d’exécution automatisés de moins de 5 heures pour des lots de 80 échantillons, une variabilité réduite liée à l’opérateur et une meilleure reproductibilité. Le système permet la découverte à grande échelle de biomarqueurs, des études longitudinales sur les maladies et des recherches multicentriques complètes. La nouvelle suite Proteograph sera commercialement disponible à partir du 1er juin 2025, via des achats directs et le Technology Access Center de Seer.
Seer (NASDAQ: SEER) hat auf der ASMS 2025 seine neue Proteograph® Produktlinie vorgestellt, die den Proteograph ONE Assay und das SP200 Automatisierungsgerät umfasst. Die verbesserte Plattform ermöglicht bahnbrechende Fortschritte in der proteomischen Analyse und verarbeitet über 1.000 Proben pro Woche pro Gerät – das Doppelte der bisherigen Kapazität. Der neue Workflow senkt die Analysekosten pro Probe um 60% im Vergleich zur Version von 2021 und identifiziert bis zu 10-mal mehr Proteine als traditionelle Massenspektrometrie-Verfahren.
Zu den wichtigsten Verbesserungen zählen automatisierte Laufzeiten von unter 5 Stunden für Chargen mit 80 Proben, reduzierte durch Bediener verursachte Variabilität und verbesserte Reproduzierbarkeit. Das System ermöglicht großangelegte Biomarker-Entdeckungen, longitudinale Krankheitsstudien und umfassende multizentrische Forschungen. Die neue Proteograph Produktlinie wird ab dem 1. Juni 2025 kommerziell erhältlich sein – sowohl im Direktkauf als auch über das Technology Access Center von Seer.
- Doubles throughput to over 1,000 samples per week per SP200 instrument
- Reduces per-sample analysis cost by 60% compared to 2021 release
- Identifies up to 10x more proteins than traditional mass spec workflows
- Achieves automated run time of under 5 hours for 80-sample batches
- Reduces operator-induced variability through automation
- None.
Insights
Seer's new Proteograph workflow doubles sample throughput while cutting costs by 60%, enabling first truly scalable deep proteomics.
Seer's newly announced Proteograph ONE and SP200 Automation Instrument represents a significant technological leap in the mass spectrometry-based proteomics market. The core advancement is remarkable: doubling throughput to over 1,000 samples weekly per instrument while reducing per-sample costs by approximately
What makes this particularly noteworthy is that Seer has addressed the three critical barriers that have historically limited proteomics research at scale: throughput limitations, workflow variability, and prohibitive costs. The automation component is especially valuable - reducing the 'human factor' variability with a sub-5-hour automated run time enables consistent 80-sample batches within standard work shifts.
The technology's ability to identify up to 10 times more proteins than traditional mass spec workflows while maintaining this scale is unprecedented. This positions Seer uniquely in the proteomics space, enabling research applications previously considered impractical, particularly population-scale studies requiring thousands of samples.
Endorsements from leading academic researchers like Professors Josh Coon and Gary Patti add credibility, as they specifically highlight the value of scale and reproducibility - critical factors for institutional adoption. The company's planned presentations at ASMS 2025 suggest significant application breadth, from neurodegenerative disorders to cancer biomarker discovery.
This innovation directly addresses the fundamental constraint in proteomics research - the inability to study proteins at genomic scale despite their critical biological role. By enabling true population-scale deep, unbiased proteomic studies, Seer is expanding the total addressable market for their technology and potentially accelerating adoption across academic, pharmaceutical, and clinical research markets.
REDWOOD CITY, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced the launch of its new Proteograph® Product Suite, featuring the Proteograph ONE Assay and SP200 Automation Instrument—its most advanced solution yet for scalable, high-resolution, mass spec-based proteomics. Seer’s newest innovation, debuting at the upcoming American Society for Mass Spectrometry (ASMS) annual conference in Baltimore, MD, overcomes the challenges of large-scale proteomic studies that had been hindered by limited throughput and prohibitive costs. It significantly enhances the flagship Proteograph Product Suite’s ability to achieve the throughput, efficiency, and depth required for the world’s first true population-scale deep, unbiased proteomic studies.
With the new Proteograph workflow, Seer achieves a transformative milestone by significantly improving the scalability, reproducibility, and affordability of deep proteomic analysis. These advancements push the boundaries of the original capabilities of the Proteograph Product Suite launched in 2021, addressing historical industry-wide limitations where deep workflows faced challenges scaling efficiently, manual handling introduced variability, and large-scale studies were hindered by prohibitive costs.
The streamlined Proteograph workflow processes more than 1,000 samples per week on a single SP200 instrument, enabling mass-spec based proteomic analysis at a depth, speed and scale that were previously not possible. The new offering also takes advantage of operational efficiencies and Seer’s volume-based pricing model to reduce the per-sample cost of proteomic analysis by about
“The introduction of the new Proteograph workflow marks a defining moment for proteomics,” said Omid Farokhzad, Chair and CEO of Seer. “It delivers on the promise of measuring the proteome deeply, reproducibly, and at scale, and allows unbiased proteomics to take its central role at the core of the next generation of scientific and medical discovery. With the launch of Proteograph ONE, we are continuing to change the arc of proteomic research and unleash the power of the proteome.”
Proteomic insights increasingly drive advances in personalized medicine, capturing biological context that is impossible with genomics or transcriptomics alone. Seer’s Proteograph workflow overcomes longstanding barriers to deep, unbiased proteomics, empowering researchers to explore the complexity of the proteome at a speed, cost, and scale previously unimaginable.
Key Capabilities of the New Proteograph Product Suite:
- Higher Throughput: Processes over 1,000 samples per week per SP200 instrument—doubling throughput without a tradeoff in performance
- Operational Efficiency: Streamlined workflow helps lower per-sample analysis cost by about
60% since 2021 - Automated Workflow: Reduces operator-induced variability and adds unmatched robustness for the processing of valuable biological samples
- Faster Turnaround: Automated run time of under 5 hours, enabling 80-sample batches to be completed comfortably within an 8-hour shift
- Deep, Unbiased Analysis: Identifies up to 10 times more proteins than traditional mass spec workflows
Seer at the ASMS 2025 Annual Conference
In addition to the product launch, Seer and its collaborators will unveil new scientific data at ASMS 2025, showcasing the transformative impact of the Proteograph Product Suite in Alzheimer's disease, cancer, and drug development research. A breakfast seminar featuring renowned proteomics experts Professors Josh Coon and Gary Patti will present compelling findings from their early access experience with the Proteograph ONE workflow.
“The original Proteograph workflow was a game-changer for mass spec-based plasma proteomics, allowing us to explore the complexity of the plasma proteome in a more complete and robust way than previously possible,” said Josh Coon, PhD, Professor of Biomolecular Chemistry and Chemistry at the University of Wisconsin-Madison. “I am super excited about the 2X boost in throughput we’ll achieve with the Proteograph ONE workflow and the population scale studies it will enable.”
Until now, deep proteomic research at a meaningful scale was fundamentally impossible, because deep workflows did not scale, manual handling introduced extensive variability, and affordability was out of reach. But Seer’s Proteograph ONE overcomes these entrenched barriers, delivering deep, reproducible, and scalable proteomic analysis at unprecedented affordability and consistency.
“We have evaluated all kinds of different proteomic technologies looking for the right mix of depth, reproducibility, and throughput needed for our large-scale research projects,” said Gary Patti, PhD, Professor of Chemistry, Genetics, and Medicine at Washington University in St. Louis. “Seer’s solution has always been unmatched in its depth and robustness—and now it’s further scalable and more cost-effective too. This allows us to assess the complexity of the proteome in our population studies at unprecedented resolution.”
Scientific Highlights from Seer and Collaborators Presenting at the ASMS 2025 Annual Meeting:
- Seer
Title: Applying deep, unbiased plasma proteomics to understand dementia classification, cognitive decline and pTau-217 biology in a 1,786-sample study
Poster: TP 083
Date: June 3 - Seer
Title: Pythia: A Fast, Sensitive, and Accurate Search Engine for Quantitative DIA Proteomics
Poster: WP 317
Date: June 4 - Seer
Title: Sensitive, comprehensive, and hi-fidelity cellular proteome analysis using a simplified lysis procedure and nanoparticle-mediated automated sample preparation
Poster: ThP 643
Date: June 5 - Thermo Fisher Scientific
Title: Transforming Cancer Biomarker Discovery Through Maximum ID and High-Throughput Plasma Proteomics Workflows
Poster: MP 072
Date: June 2 - Thermo Fisher Scientific
Title: Comprehensive and High-Throughput Plasma Proteome Profiling for Biomarker Discovery using a modified Thermo Scientific Orbitrap Astral Mass Spectrometer
Poster: MP 078
Date: June 2 - Thermo Fisher Scientific
Title: LC-MS Workflows for Diverse Omics Analysis of Plasma Samples in a Mini Cancer Cohort Using the Orbitrap Astral Mass Spectrometer
Poster: MP 096
Date: June 2 - University of Wisconsin-Madison
Title: Plasma multi-omics analysis to define Long-COVID molecular signatures
Poster: MP 460
Date: June 2 - University of Wisconsin-Madison
Title: A Technical Evaluation of Plasma Proteomics Technologies
Poster: WP 651
Date: June 4 - INSERM
Title: Goldmining in the Plasma Proteome: benchmark of different enrichment strategies for Extracellular Vesicles, platelet and cytokines and chemokines content
Poster: MP 084
Date: June 2 - Discovery Life Sciences
Title: Analytical Considerations for Biomarker Analysis from Plasma Samples for Large Cohort and Clinical Exploratory Studies
Poster: TP 070
Date: June 3 - Evotec
Title: Nanoparticle-based proteomics by mass spectrometry in plasma samples from Huntington’s disease cohort
Poster: TP 110
Date: June 3 - Washington University and Panome Bio
Title: Addressing the Plasma Proteomics Needs of Large-Scale Clinical Cohorts
Poster: WP 677
Date: June 4 - PrognomiQ
Title: Automated Quantitative Analysis of 1951 Subject Cancer Cohort Study in Multiple Reaction Monitor (MRM) LC-MS
Poster: ThP 590
Date: June 5 - University of Washington
Title: Plasma Proteomics Using Mag-Net and Proteograph XT Enrichment Enables Multi-Faceted Biomarker Discovery with Complementary Protein and Peptide Coverage
Poster: ThP 053
Date: June 5
The new Proteograph Product Suite will be commercially available beginning June 1 via instrument and kit purchases and as a service through the Seer Technology Access Center (STAC).
To learn more about the Proteograph ONE Assay and SP200 Automation Instrument visit Booth #746 during ASMS 2025 or contact us at pr@seer.bio.
About Seer, Inc.
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics—delivering insights with a scale, speed, precision, and reproducibility previously unattainable. Seer’s Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges conventional methods have failed to overcome. Traditional proteomic technologies have struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer’s robust and scalable workflow consistently reveals biological insights that others cannot. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information about Seer’s differentiated approach and ongoing leadership in proteomics, visit www.seer.bio.
Media Contact:
Consort Partners
Investor Contact:
Carrie Mendivil
FAQ
What are the key features of Seer's new Proteograph ONE workflow announced at ASMS 2025?
When will Seer's new Proteograph Product Suite be commercially available?
How does SEER's new Proteograph workflow improve efficiency compared to its 2021 version?
What scientific applications will Seer showcase for the Proteograph system at ASMS 2025?
